Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: Clin Cancer Res. 2021 Jul 1;27(18):5141–5150. doi: 10.1158/1078-0432.CCR-21-0982

Fig 1. Organoid Workflow Diagram.

Fig 1.

Incorporating patient matched immune system into tumor organoids, followed by immunotherapy testing, and analysis. PBMC, lymph nodes or spleen, provided immune system elements for PTO enhancement(iPTOs). Blood iPTOs were enhanced with PBMCs. Lymph iPTOs were enhanced with lymph nodes or spleen tissue. PTOs were biofabricated utilizing a collagen-based ECM. After 7 days of incubation, PTOs and iPTOs were treated with Pembrolizumab, Ipilimumab, and Nivolumab containing media for 3 days, prior to analysis of immunotherapy efficacy. (Created with Biorender - biorender.com).